Medical Penicillin Market Scope
Penicillin is a group of antibacterial drugs that attack a good range of bacteria and are a category of beta-lactam antibiotics. The invention and manufacture of penicillins have transformed the face of drugs as these drugs have saved many lives. Penicillin was the primary antibiotic discovered from the mold Penicillium notatum. Penicillins block the protein supports that link the peptidoglycans together. This avoids the bacterium from closing the holes in its cell walls. Penicillium chrysogenum, was later found to offer the very best yield of penicillin, and was subsequently used for the commercial production of this antibiotic. In 2017, 15.8% of isolates collected from the Gonococcal Isolate Surveillance Project (GISP) sites were immune to penicillin.
The Medical Penicillin market study is segmented by Type (Natural Penicillins [Benzylpenicillin, Phenoxymethylpenicillin], Penicillinase Resistant, Extended Spectrum and Anti-Pseudomonal), by Application (Respiratory tract infections, Skin and soft tissue infections., Endocarditis, Bone and joint infections, UTIs and Others [Intra-abdominal infections, Septicemia]) and major geographies with country level break-up.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Medical Penicillin market throughout the predicted period.
Pfizer (United States), Merck & Co., Inc. (United States), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Astellas Pharma Inc. (Japan), GlaxoSmithKline plc. (United Kingdom), Gilead Sciences Inc. (United States), Toyama Chemical Co., Ltd (Japan), Sanofi Aventis SA (France), Eli Lilly (United States), Biogen IDEC (United States), Bayer HealthCare AG (Germany), Abbot Laboratories (United States), Aurobindo Pharma USA (United States) and Hindustan Antibiotics (India) are some of the key players that are part of study coverage.
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
AdvanceMarketAnalytics has segmented the market of Global Medical Penicillin market by Type, Application and Region.
On the basis of geography, the market of Medical Penicillin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Penicillin finished pharmaceutical manufacturers, including repackers, are required by the CGMP regulations to establish a comprehensive control strategy designed to prevent cross-contamination of other drugs with penicillin. These requirements include:, 21 CFR 211.42(d): Separation of facility and equipment, 21 CFR 211.46(d): Separate air handling systems (HVAC), 21 CFR 211.176: Test for Traces of penicillin where possible exposure exists. and Penicillin active pharmaceutical ingredients (APIs) are also required to be manufactured under CGMPs in accordance with section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act.
- Growing Demand for Generic Drugs
- Creating Awareness by Various Government and Non-Government Organizations to Control the Bacterial Infectious Disease among People
- Rising Investment in Research & Development Activity with New Product Innovations
- New Product Development and Usage of Penicillin In Cell Cultures
- Stringent Government Regulations to Limit the Use of Antibiotics and Patent Expiry for Antibiotic
- Allergic Reactions Include urticaria, sever pruritus, fever, joint swelling, hemolytic anemia, nephritis, and anaphylaxis
- Gastrointestinal Disturbances
Key Target AudienceManufacturers of Medical Penicillin, Suppliers of Medical Penicillin, Wholesalers, Distributors and Retailers of Medical Penicillin, Pharmaceutical Industry and Governmental and Regulatory Bodies
Frequently asked questions:1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
2. How big is the Medical Penicillin Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.